Arrowhead Pharmaceuticals Inc

Financials

Cash from operating activities 95.4 M171.22 M136.13 M153.89 M462.85 M179.55 M 46.76 M Cash from investing activities -240.78 M141.68 M5.42 M96.16 M420.07 M129.29 M 76.13 M Cash from financing activities 257.95 M11.3 M65.19 M253.05 M870.52 M74.01 M 68.12 M Free cash flow 83.45 M147.66 M83.35 M-22.85 M321.38 M156.85 M 29.43 M

Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.

ARWR

Financials

Arrowhead Pharmaceuticals Inc

新闻

中邮证券：siRNA药物机制优势突出递送为核心技术

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

GSK Strikes $1 Billion China RNA Deal

国联民生证券：小核酸重构减肥逻辑 INHBE与ALK7靶点初步验证

箭头制药股票前景：高盛预见2026年催化剂

Arrowhead Pharma stock outlook: Goldman Sachs sees 2026 catalysts ahead

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2026 Earnings Call Transcript

Arrowhead Pharma earnings beat by $0.10, revenue topped estimates

招商证券国际：重申石药集团(01093)“中性”评级中国创新药进入全球管线

摩根士丹利维持箭头制药评级，股价保持稳定

Arrowhead Pharma stock holds steady as Morgan Stanley maintains rating

箭头制药开始首个双靶点RNAi疗法的1/2a期临床试验